Observational study finds zoledronate efficacy varies by disease stage in osteonecrosis, indicating treatment constraints.
Zoledronate treatment is more likely to be effective in male patients with early-stage osteonecrosis (ARCO I-II), whereas advanced-stage disease (ARCO III-IV) may not respond well. Moreover, an accelerated bone resorption rate, indicated by elevated ICTP levels after zoledronate infusion, is associated with an increased risk of treatment failure.
No takes yet. Share an insight, caveat, or question.
Moksi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: